Reactive Oxygen Species and Cancer Cell Metabolism

A special issue of Applied Sciences (ISSN 2076-3417). This special issue belongs to the section "Applied Biosciences and Bioengineering".

Deadline for manuscript submissions: closed (31 December 2020) | Viewed by 3085

Special Issue Editors


E-Mail Website
Guest Editor
Laboratory for Oxidative Stress, Division of Molecular Medicine, Rudjer Boskovic Institute, 10000 Zagreb, Croatia
Interests: oxidative stress; reactive oxygen species (ROS); lipid peroxidation; cancer; cancer stem cells; cellular and extracellular antioxidants; Nrf2; metabolic reprogramming
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Division of Molecular Medicine, Rudjer Boskovic Institute, Bijenicka 54, 10000 Zagreb, Croatia
Interests: oxidative stress; antioxidative defense; lipid peroxidation; reactive oxygen species (ROS); cancer; cancer stem cells; aquaporins
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Cancer still remains a puzzle with the myriad pieces not fitting to the general picture due to cancer-known heterogeneity not only between cancers of different origin but within the same cancer as well. The development and progression of cancer are highly affected by the environmental cues fostering metabolic reprogramming for the promotion of cancer growth. Numerous factors, including reactive oxygen species (ROS), are contributing to these processes. Not only are ROS known for their detrimental role, governing genetic mutations that can support eventual cancer development, but they can also lead these transformed cells to apoptosis by activating cellular pathways, thus causing cancer growth arrest. Today, increasing perception recognizes ROS as “cellular fate decision regulators”, the generation of which is highly intertwined with the metabolic switches and antioxidative machinery. Cells are thus exploiting their signaling abilities to regulate their own functions or the ones of neighboring cells.

In this Special Issue, we invite original and review papers exploring the role of ROS, the impact of the metabolic reprogramming, and the cellular antioxidative machinery to the cancer growth. Papers highlighting the importance of ROS, metabolism, and antioxidants in anticancer therapy are also highly appreciated.

Dr. Lidija Milković
Dr. Ana Čipak Gašparović
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Applied Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • oxidative stress
  • reactive oxygen species (ROS)
  • cancer
  • cell signaling
  • metabolic reprogramming
  • antioxidants
  • nuclear factor erythroid 2-related factor 2 (NRF2)
  • anticancer therapy

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

15 pages, 2405 KiB  
Article
Interaction of 2,6,7-Trihydroxy-Xanthene-3-Ones with Iron and Copper, and Biological Effect of the Most Active Derivative on Breast Cancer Cells and Erythrocytes
by Přemysl Mladěnka, Jana Karlíčková, Marcel Hrubša, Elma Veljović, Samija Muratović, Alejandro Carazo, Akash Shivling Mali, Selma Špirtović-Halilović, Luciano Saso, Milan Pour and Kemal Durić
Appl. Sci. 2020, 10(14), 4846; https://doi.org/10.3390/app10144846 - 15 Jul 2020
Cited by 9 | Viewed by 2477
Abstract
Metal chelators can be potentially employed in the treatment of various diseases, ranging from metal overload to neoplastic conditions. Some xanthene derivatives were previously reported to complex metals. Thus, in a search for a novel iron or copper chelator, a series of 9-(substituted [...] Read more.
Metal chelators can be potentially employed in the treatment of various diseases, ranging from metal overload to neoplastic conditions. Some xanthene derivatives were previously reported to complex metals. Thus, in a search for a novel iron or copper chelator, a series of 9-(substituted phenyl)-2,6,7-trihydroxy-xanthene-3-ones was tested using a competitive spectrophotometric approach. The most promising compound was evaluated in biological models (breast adenocarcinoma cell lines and erythrocytes). In general, substitution of the benzene ring in position 9 had a relatively low effect on the chelation. Only the trifluoromethyl substitution resulted in stronger chelation, probably via a positive effect on solvation. All compounds chelated iron, but their copper-chelating effect was only minimal, since it was no longer observed under highly competitive conditions. Interestingly, all compounds reduced both iron and copper. Additional experiments showed that the trifluoromethyl derivative protected erythrocytes and even cancer cells against excess copper. In summary, the tested compounds are iron chelators, which are also capable of reducing iron/copper, but the copper-reducing effect is not associated with increased copper toxicity. Full article
(This article belongs to the Special Issue Reactive Oxygen Species and Cancer Cell Metabolism)
Show Figures

Graphical abstract

Back to TopTop